Pfizer Pulls Celebrex's FAP Indication Quickly After Slow Trial Results
This article was originally published in The Pink Sheet Daily
Executive Summary
The European Medicines Agency issues a formal review, even though the claim had been withdrawn, in order to discourage off-label use.
You may also be interested in...
COX-2 Inhibitors No Longer The Pits: Tragara's Apricoxib Shows Potential In Phase II APRICOT-L Lung Cancer Trial
Tragara Pharmaceuticals, Inc. may have found a beneficial use for a COX-2 inhibitor in oncology, and it involves using a urine test, not a biopsy, to match non-small cell lung cancer patients with the therapy.
COX-2 Inhibitors No Longer The Pits: Tragara's Apricoxib Shows Potential In Phase II APRICOT-L Lung Cancer Trial
Tragara Pharmaceuticals, Inc. may have found a beneficial use for a COX-2 inhibitor in oncology, and it involves using a urine test, not a biopsy, to match non-small cell lung cancer patients with the therapy.
Roche Succeeds In Changing EMA Ruling On Avastin
The Committee for Medicinal Products for Human Use has reversed its previous rejection and is granting an indication for treatment of first-line breast cancer in combination with capecitabine.